Trial Profile
Expanded Access Program for Inotersen (ISIS 420915) in Patients With Hereditary Transthyretin Amyloidosis (hATTR)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Inotersen (Primary)
- Indications Amyloid polyneuropathy
- Focus Expanded access; Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 26 May 2020 Results (N267), pooled analysis of 5 studies (NEURO-TTR, OLE, EAP, ATU, and IST) assessing outcomes of enhanced monitoring for thrombocytopenia in patients receiving inotersen presented at the 6th Congress of the European Academy of Neurology
- 08 Nov 2018 Status changed from recruiting to completed.
- 08 Jan 2018 Status changed from planning to recruiting.